Watch KYNB. Know when insiders buy.
One email the day a filing lands. Free.
KYNB
KYNTRA BIO, INC.
7.07
−0.03 −0.35%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
32
FLAG · shorts 32
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $28.6MP/E 0.2DIV YIELD —FCF YIELD -132.86%REV TTM $4.6M −37.1%NET INCOME $183.2MNET DEBT $24.4M52W 6.46 – 12.38SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | −$1.5M | −209.3% | 100.1% | −$17.6M | $12M | — | 2.96 | −$4M | $0 | −$4M | Aug 13 |
| Q1 2026 · Mar 31 | $3.7M | +36.5% | -9.8% | −$13.8M | −$15.2M | −427.6% | -3.76 | −$13.9M | $0 | −$13.9M | May 12 |
| Q4 2025 · Dec 31derived | $1.3M | −59.3% | 78.2% | −$13.5M | −$14.2M | −179.1% | -3.53 | −$18.3M | $0 | −$18.3M | Mar 16 |
| Q3 2025 · Sep 30 | $1.1M | +774.8% | 105.4% | −$5.4M | $200.6M | — | 49.61 | −$1.8M | $9K | −$1.9M | Nov 10 |
| Q2 2025 · Jun 30 | $1.3M | +35.1% | 93.7% | −$12.1M | −$7.6M | — | -1.88 | $12.7M | $13K | $12.7M | Aug 13 |
| Q1 2025 · Mar 31 | $2.7M | −89.2% | 90.8% | −$14.9M | $4.6M | — | 1.15 | $2.7M | $16K | $2.7M | May 12 |
| Q4 2024 · Dec 31derived | $3.1M | — | 286.5% | −$7.1M | $18M | — | 4.54 | −$30.5M | $141K | −$30.6M | Mar 16 |
| Q3 2024 · Sep 30 | $123K | −99.7% | 161.0% | −$47.7M | −$17.1M | — | -4.25 | −$8.4M | $82K | −$8.5M | Nov 10 |
| Q2 2024 · Jun 30 | $998K | — | 86.0% | −$46.4M | −$15.5M | — | -3.89 | −$39.9M | $14K | −$39.9M | Aug 11 |
| Q1 2024 · Mar 31 | $25.4M | — | 15.9% | −$49.2M | −$32.9M | — | -0.33 | −$59.3M | $29K | −$59.3M | May 12 |
| Q4 2023 · Dec 31derived | −$73.8M | — | 87.2% | −$95.1M | −$56.2M | — | -0.57 | −$18.3M | $251K | −$18.6M | Mar 17 |
| Q3 2023 · Sep 30 | $40.1M | — | 89.4% | −$63.5M | −$63.6M | — | -0.65 | −$84.5M | $684K | −$85.2M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $6.4M | 91.4% | −$45.9M | $183.5M | 2848.6% | 45.37 | −$4.8M | $38K | −$4.8M | — | — |
| FY2024 · to Dec 31 | $29.6M | 47.5% | −$150.4M | −$47.6M | -160.6% | -11.89 | −$138M | $266K | −$138.3M | — | — |
| FY2023 · to Dec 31 | $46.8M | 91.5% | −$322.7M | −$284.2M | -607.3% | -2.92 | −$315M | $2.5M | −$317.5M | — | — |
| FY2022 · to Dec 31 | $140.7M | 85.6% | −$301M | −$293.7M | -208.7% | -3.14 | −$145.9M | $3.7M | −$149.7M | — | — |
| FY2021 · to Dec 31 | $235.3M | 94.5% | −$288.5M | −$290M | -123.3% | -3.14 | −$82.2M | $5.2M | −$87.4M | — | — |
| FY2020 · to Dec 31 | $176.3M | 95.0% | −$191.9M | −$189.3M | -107.4% | -2.11 | $81.6M | $4M | $77.6M | — | — |
Every number comes from KYNTRA BIO, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.